More than half (53%) of patient groups view US drugmakers favorably, an 8-point drop since last year, tied to funding and engagement cuts.
FDA head Marty Makary is likely to be fired. While pharma’s relationship with him has been uneven, drugmakers may be even more concerned about Kennedy’s influence over his successor.
Google Health app will use device data and medical records to deliver health insights, intensifying competition among consumer health wearables and AI tools.
Fake health ads are flooding Facebook, meaning marketers must help consumers spot red flags like fake urgency, bogus logos, and so-called miracle cures.
Novo beat Q1 expectations thanks to Wegovy pill buzz as Lilly readies rival Foundayo, setting up weight loss drugs’ next ad showdown.
As more consumers turn to AI for health advice, embedded clinical tools aim to build trust where confidence remains low.
Like other big health insurers, CVS is exiting unprofitable markets while trimming members—a playbook to earn Wall Street approval as patients scramble for new coverage.
Pennsylvania argues in a new lawsuit that Character.AI’s “psychiatrist” bots cross into illegal practice, not just risky advice.
Nearly 60% value mental health more this year than 5 years ago, but cost and access hurdles prevent them from getting medical care.
Pharma’s new D2C sites can reduce barriers to care and treatment, but brands boost awareness of their platforms to drive adoption.
Unless Congress codifies drug pricing deals, TrumpRx risks serving more as political optics than a driver of meaningful patient affordability.
Doctors guide consumers’ clinical health decisions, but AI and influencers more often steer daily health habits.
The move could curb telehealth’s copycat obesity drugs and steer patients back to branded options.
Near-universal AI adoption in healthcare is approaching. Now organizations want their experiments to prove ROI.
Health benefits leaders often fail to inform workers about Rx savings options because opaque PBM contracts create confusion, driving the rise of more transparent, direct-to-employer pharma models.
It generated nearly $20 billion sales in Q1, led by GLP-1 brands Mounjaro and Zepbound, positioning it ahead of a pill rivalry with Novo.
The FDA is testing real-time data feeds in studies that could speed drug approval times but also changes how drug companies submit data for review.
Accelerated dealmaking hits $66 billion as big pharma players look to mitigate steep patent cliff losses and diversify pipelines.
Consumers value both AI and humans for health tasks but defer to humans for high-stakes guidance, meaning AI companies should position their tools as assistive rather than replacements for doctors.
93% make short- and long-term health changes from tracker data, outpacing older cohorts and redefining what effective apps must deliver.